ASCO GU 2018 Prostate Cancer
Viewing 64-83 of 88 articles
ASCO GU 2018: Hypoxia related mRNA biomarker to predict biochemical failure and metastasis for prostate cancer.
ASCO GU 2018: First Presentation - SPARTAN: A Study of Apalutamide (ARN-509) in Men with Non-Metastatic Castration-resistant Prostate Cancer
ASCO GU 2018: First Presentation - PROSPER: Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)
ASCO GU 2018: Transcriptomic Heterogeneity of Androgen Receptor Activity in Primary Prostate Cancer: Identification and Characterization of a Low AR-active Subclass
ASCO GU 2018: Medical Resource Utilization of Abiraterone Acetate Plus Prednisone added to ADT in Metastatic Castration-naive Prostate Cancer: Results from LATITUDE
ASCO GU 2018: Impact of Decipher test on adjuvant and salvage treatments received following radical prostatectomy
ASCO GU 2018: TPS383 - ARASENS: A Phase 3 Trial of Darolutamide in Combination with Docetaxel for Men with Metastatic Hormone-sensitive Prostate Cancer
ASCO GU 2018: The FALCON Trial: Impact of 18F-fluciclovine PET/CT on Clinical Management Choices for Men with Biochemically Recurrent Prostate Cancer
ASCO GU 2018: Improving risk-stratification of localized prostate cancer in a prospective active surveillance cohort
ASCO GU 2018: Enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic CRPC patients metastatic to bone (PEACE III)
ASCO GU 2018: Genomic and Phenotypic Evidence for Prostate Cancer Osteomimicry in Circulating Tumor Cells from Men with Metastatic Castration Resistant Prostate Cancer Treated with Radium-223
ASCO GU 2018: Multivitamin Use and Risk of Prostate Cancer Recurrence: Data from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE)
ASCO GU 2018: Randomised Phase III Trial of Enzalutamide in Androgen Deprivation Therapy with Radiation Therapy for High Risk, Clinically Localized Prostate Cancer: ENZARAD (ANZUP 1303)
ASCO GU 2018: The Association Between Physician Trust and Prostate Specific Antigen Screening: Implications for Shared Decision Making.